Avalyn Pharma Earnings Call Transcripts
Fiscal Year 2026
-
Inhaled AP01 and AP02 seek to improve tolerability and enable combinations; MIST enrolled 398 patients, while AP02 is designed to select a phase III dose in 12 weeks. Nearly $400m in cash is expected to fund operations into 2029, assuming phase III funding for both programs.
-
Focused on inhaled therapies for pulmonary fibrosis, the company leverages a patented nebulizer and strong IP to address major unmet needs in a large market. Lead candidates show improved tolerability and efficacy, with pivotal data expected next year and a robust pipeline advancing.
-
The company is advancing inhaled therapies for pulmonary fibrosis, aiming to improve tolerability and efficacy over current oral treatments. Key programs are in late-stage clinical trials, with strong long-term data and a robust financial position to support further development and potential market leadership.